GlaxoSmithKline Pharmaceuticals Shareholding Pattern
- Market cap
- ₹44,821 crore
- P/E
- 42.0
- P/B
- 19.77
- ROE
- 49.1%
- Dividend yield
- 1.20%
As of 30-JUN-2026, promoters held 75.00% of GlaxoSmithKline Pharmaceuticals (0.00 pp from 31-MAR-2026), foreign institutional investors 4.79%, domestic institutions 7.80% and the public 12.41%.
Source: Shareholding patterns filed with the stock exchanges (company filings). Data as of 7 October 2026. How this data is compiled.
GlaxoSmithKline Pharmaceuticals shareholding pattern — frequently asked questions
What is the promoter holding in GlaxoSmithKline Pharmaceuticals?
Promoters held 75.00% of GlaxoSmithKline Pharmaceuticals as of 30-JUN-2026, unchanged from 75.00% in 31-MAR-2026.
How much do FIIs hold in GlaxoSmithKline Pharmaceuticals?
Foreign institutional investors held 4.79% of GlaxoSmithKline Pharmaceuticals as of 30-JUN-2026, a change of +0.17 pp from the previous quarter.
How much do domestic institutions hold in GlaxoSmithKline Pharmaceuticals?
Domestic institutional investors, including mutual funds and insurers, held 7.80% of GlaxoSmithKline Pharmaceuticals as of 30-JUN-2026 (+0.12 pp from the previous quarter).
Who owns GlaxoSmithKline Pharmaceuticals?
As of 30-JUN-2026, GlaxoSmithKline Pharmaceuticals' shareholders were promoters (75.00%), foreign institutional investors 4.79%, domestic institutions 7.80% and the public 12.41%, as filed with the stock exchanges.
Same Data For Peers
Trade GlaxoSmithKline Pharmaceuticals With ATS
Track GLAXO live and place orders from the Pocket app or the Pocket Web terminal with an ATS trading and demat account.
Figures are for information only and are not investment advice or a recommendation to buy, sell or hold any security. Investments in securities are subject to market risks; read all related documents carefully before investing.